Kornimate/medical-research-clean huggingface dataset:
primordial dwarfism registry

Conditions: MOPDII; RNU4atac-opathy (e.g. MOPDI/III, Lowry-Wood Syndrome, Roifman Syndrome); Meier-Gorlin Syndrome; Saul-Wilson Syndrome; Ligase 4 Syndrome; Microcephalic Primordial Dwarfism

Summary: the goal of this registry is to collect information on individuals with forms of microcephalic primordial dwarfism. the study team hopes to learn more about these conditions and improve the care of people with it by establishing this registry.

the goal of this registry is to collect information on individuals with forms of microcephalic primordial dwarfism. the registry will enable detailed natural history studies of mopd ii and associated conditions. the study team hopes that identification of risk factors will allow for preventative treatments and thus a better quality of life for individuals with these diagnoses. this study is limited to chart review, after signed informed consent obtained. there will be no additional visits or time in clinic because of participation in this registry. this study involves only the collection and storage of data extracted from the medical record. records that may be requested and reviewed as a part of this study include but may not be limited to: specialist evaluations, surgical reports, results of blood and urine tests, genetic testing, x-rays, ct/mri/mra imaging. there are no special procedures, visits, or expectations of the individual as a result of participation in this registry. no one will be asked to have any specific testing for the sole purposes of this research.

Eligibility criteria:
inclusion criteria: * individuals with mopdii, mopdi/iii, meier-gorlin syndrome, or unclassified or closely related types of microcephalic primordial dwarfism as diagnosed by a medical provider are eligible for this registry. exclusion criteria: * individuals without microcephalic primordial dwarfism or closely related conditions

Keywords: microcephalic primordial dwarfism
treatment of lumbar spinal stenosis; comparison of two different surgical methods; mini-invasive decompression to x-stop

Conditions: Lumbar Spinal Stenosis; Radiculopathy

Summary: the purpose of this study is to compare two surgery methods on lumbar spinal stenosis: minimal invasive decompression and x-stop. it is a prospective randomized multicenter study including patients with lumbar spinal stenosis on one or two levels, and neurogenic intermittent claudication. effect assessment will include measures of pain and self-evaluated health condition, a full economical evaluation, and areal measurements (mr imaging and roentgen analyses)


Eligibility criteria:
inclusion criteria: * neurogenic intermittent claudication due to lumbar spinal stenosis * diagnosed on mri in maximum two levels * walking distance on 250 metres * symptom relief on flexion of the lumbar spine * duration of the symptoms more than 6 months * non-operative treatment is tried or considered as not indicated exclusion criteria: * vascular claudicatio intermittens * spinal stenosis on more than 2 levels * cauda equina syndrome * severe paresis * clinical monoradiculopathy * grave scoliosis * previous lumbar surgery * degenerative spondylolisthesis more than 25% * spondylolysis with listhesis * osteoporotic fracture in lumbal column * clinical and radiological (both) arthritis in the hip joint * asa \>3 * verified polyneuropathy on neurophysiological test

Keywords: decompression, surgical x-stop lumbar decompression spinal stenosis radiculopathy
effectiveness of adding morphine to intraosseous vancomycin for pain control in total knee arthroplasty

Conditions: Primary Total Knee Arthroplasty; Intraosseous Morphine Injection; Knee Osteoarthritis

Summary: study investigators propose to investigate if a bony injection of pain medication during a knee replacement will help pain levels following primary knee replacement surgery. to investigate this, 86 patients will be enrolled. half of the patients will receive a bony injection of antibiotics with morphine (pain medication) while the other half will receive a bony injection of antibiotics with placebo (no pain medication). following surgery, patient pain levels and pain medication consumption will be measured. the injection is intraosseous meaning in the bone. the needle pierces the bone and the medication is injected into the bone. the site of injection is on the anterior (front) of the upper portion of the tibia. the medications are vancomycin (antibiotic) and morphine (pain medication) which are mixed in separate syringes and then injected. intraosseous vancomycin is standard of care while intraosseous vancomycin with morphine is also standard of care, depending on operating surgeon.


Eligibility criteria:
inclusion criteria: 1. 18-100 years old 2. primary total knee arthroplasty 3. participants must be able to consent for themselves 4. capable and comfortable with text messaging exclusion criteria: 1. non-primary total knee arthroplasty 2. intraoperative or postoperative deviation from standard of care 3. post-traumatic surgical indication 4. post-infectious surgical indication 5. chronic narcotic use or history of narcotic addiction 6. allergy to vancomycin 7. allergy to morphine 8. inability to receive spinal anesthesia 9. inability to receive intraoperative adductor canal block 10. inability to provide informed consent for the study 11. inability to speak english fluently
contemporary characteristics of penile cancer

Conditions: Penile Carcinoma; Squamous Cell Carcinoma of the Penis

Summary: this study develops a prospective database of patients who are evaluated and treated for penile cancer. this will facilitate analyzing trends in cancer incidence, risk factors, treatment, complications, and tumor progression. it will also prospectively validate the importance of pathological prognostic factors previously reported and outcome related to contemporary treatment.

primary objective: i. to prospectively collect data on the presenting features, management and outcome of penile carcinoma at m.d. anderson cancer center, and harris health system and katy, sugar land, the woodlands and bay area regional care centers. outline: patients undergo data collection every 6 months for up to 15 years.

Eligibility criteria:
inclusion criteria: * all diagnosed patients with a primary penile malignancy, including those with squamous carcinoma exclusion criteria: * no patient meeting the above criteria will be excluded
aa4500 (xiaflex™, proposed name) in the treatment of dupuytren's contracture

Conditions: Dupuytren's Contracture

Summary: this was a phase 3, double-blind, randomized, placebo-controlled study conducted in the united states. subjects with a diagnosis of dupuytren's contracture in a metacarpophalangeal (mp) or proximal interphalangeal (pip) joint that resulted in a fixed flexion deformity of at least one finger, other than the thumb, that was at least 20° as measured by finger goniometry and was suitable for injection were randomized 2:1 to receive aa4500 0.58 mg or placebo. this study was designed to be part of the larger clinical program, for adult patients with dupuytren's contracture with a palpable cord, where the data from 2 pivotal placebo-controlled studies (aux-cc-857 (nct00528606) and aux-cc-859 (nct00533273)) and 7 non-pivotal studies were evaluated.


Eligibility criteria:
inclusion criteria: * subjects with a diagnosis of dupuytren's contracture, with a fixed flexion deformity of at least one finger, other than the thumb, that had a contracture at least 20°, but not greater than 100°, for mp (80° for pip) joints, caused by a palpable cord that had never been treated with aa4500. * had a positive "table top test," defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top. * judged to be in good health. exclusion criteria: * had a chronic muscular, neurological, or neuromuscular disorder that affected the hands. * had received a treatment for dupuytren's contracture, including surgery (fasciectomy or surgical fasciotomy), needle aponeurotomy/fasciotomy, or injection of verapamil and/or interferon on the selected primary joint within 90 days before the first dose of study drug. * had a known recent history of stroke, bleeding, a disease process that affected the hands, or other medical condition, which in the investigator's opinion, would make the subject unsuitable for enrollment in the study.
an awareness, courage, and love intervention to help chinese older adults in the post-pandemic era

Conditions: Loneliness; Depression; Anxiety; Social Connectedness; Subjective Well-being; Psychological Intervention; Older Adults

Summary: the purpose of this study is to explore the potential effectiveness of a one-session online awareness, courage, and love intervention for reducing loneliness, depression and anxiety symptoms, and enhancing social connectedness and subjective well-being among older adults. the study also aims to estimate the effect sizes of the awareness, courage, and love intervention.

the recruitment process will commence with referrals from local community organizations. eligible individuals will be provided with detailed information about the study, and informed consent will be obtained from those willing to participate. after the confirmation of participant recruitment, a randomization process will be implemented to ensure the equitable distribution of participants between the intervention and waitlist control groups. an independent researcher will generate computer-generated random codes for group assignment, and these codes will be securely sealed in opaque envelopes. the envelopes will be sequentially numbered, and the randomization process will remain blinded throughout to prevent bias. participants will be notified via email or text for the details of the condition they are assigned, and their willingness to engage in both the intervention and data collection will be confirmed.

Eligibility criteria:
inclusion criteria: 1. aged 60 years or older and dwelling in the community; 2. able to communicate in cantonese; 3. have access to the internet and videoconferencing devices such as a mobile phone; 4. able to give informed consent to participate. exclusion criteria: 1. severe emotional distress based on phq-4 screening assessment or presenting an imminent suicidal risk; 2. known history of autism, intellectual disability, schizophrenia-spectrum disorder, bipolar disorder, parkinson's disease, or dementia/significant cognitive impairment; 3. illiterate; 4. difficulty in communication.
surgery plus celiac nerve block for long-term pancreatic cancer pain control

Conditions: Pancreas Cancer; Biliary Tract Cancer

Summary: this is a randomized study of surgery plus chemical nerve block versus surgery plus placebo for pain control in subjects with pancreatic cancer.

thi is a study of pain control in subjects undergoing surgery for pancreatic or bile duct cancer. subjects undergoing surgery will be randomized to surgery plus celiac plexus neurolysis with ethanol injection versus surgery plus placebo injection. subjects will be followed every three months for survivorship or death to assess pain, quality of life measures, and narcotic pain control usage. the primary endpoint of pain control will be determined at one year post surgery. subjects are not required to undergo any additional diagnostic testing procedures that are not part of their routine follow-up care.

Eligibility criteria:
inclusion criteria: this study will be offered to all patients scheduled to undergo open or laparoscopic operative resection of a presumed pancreatic (any location; i.e., head, body, or tail) or distal biliary tract cancer. * physiologic suitability for major abdominal surgery * aged 18 years and older * written informed consent * ability to understand and comply with study guidelines. exclusion criteria: * pregnancy * previous, preoperative celiac nerve block * neoadjuvant chemotherapy or radiation therapy * incomplete tumor resection (r2 resection, grossly positive resection margin) * presumed ampullary or duodenal cancer based on preoperative work-up or intraoperative findings * benign tumors, neuroendocrine tumors, soft tissue tumors based on preoperative work-up or intraoperative findings * known metastatic disease

Keywords: pancreatic cancer pain
pharmacokinetic profile and dermatomal coverage of the erector spinae plane block

Conditions: Pain, Postoperative; Pain, Chest

Summary: the goals of this study are as follows: 1. to confirm the safe dosing of ropivacaine for the erector spinae plane block 2. develop a pharmacokinetic profile of the erector spinae plane block, which will help demonstrate how quickly and how closely toxic levels are reached when a routine dose of ropivacaine is given for this nerve block 3. assess numbness created by the erector spinae block when routine doses are administered


Eligibility criteria:
inclusion criteria: 1. participant's age is greater than 18 years 2. participant is undergoing a primary coronary artery bypass grafting surgery or heart valve replacement that requires a midline sternotomy incision 3. participant's surgery is being performed by dr. vig kasirajan exclusion criteria: 1. diagnosis of cirrhosis, hepatitis, primary sclerosing cholangitis 2. abnormal liver function tests demonstrated by lab results 3. allergy to lidocaine, ropivacaine, or midazolam 4. morbid obesity, defined as body mass index greater than 40 5. existing skin neuropathy on the chest or back 6. body weight less than 50 kg 7. participant is not able to provide verbal feedback, such as when the participant develops altered mental status or requires prolonged mechanical ventilation and sedation 8. participant remains intubated on post-operative day 1 9. pregnant women
testosterone replacement to alleviate pain in postmenopausal women (trapp trial)

Conditions: Pain; Opioid Use; Androgen Deficiency; Back Pain

Summary: the aim of this trial is to evaluate whether testosterone replacement results in greater improvement in pain perception, pain tolerance, sexual function, physical function and quality of life when compared with placebo in women with chronic back pain treated with opioids who have low testosterone.

this single-center, randomized, double-blind, placebo-controlled, parallel-group trial will evaluate pain and quality of life outcomes associated with 3 months of treatment with testosterone or placebo in women aged 60 years or older with chronic non-cancer back pain who are taking opioid analgesics for at least 6 months and have low testosterone.

Eligibility criteria:
inclusion criteria: * women, age 60 years and older. * chronic non-cancer back pain. * use of opioid analgesics for at least 6 months. * serum total testosterone \<8.7 ng/dl and/or free testosterone \<0.47 pg/ml. * normal mammogram within the last 12 months * endometrial thickness of \<4 mm in women with an intact uterus assessed by endometrial ultrasound. * ability and willingness to provide informed consent. exclusion criteria: * history of breast or endometrial cancer * estrogen therapy in the past 3 months * baseline hematocrit \>48%. * serum creatinine \>2.5 mg/dl. * hba1c \>9.0%. subjects on insulin therapy will be excluded. * bmi \>40 kg/m2. * uncontrolled congestive heart failure. * myocardial infarction, acute coronary syndrome, revascularization surgery or stroke within the past 3 months. * history of genetic thromboembolic disorder. * diagnosis of bipolar disorder or schizophrenia. * use of testosterone, spironolactone, finasteride or systemic ketoconazole in the past 3 months.

Keywords: opioid use pain women testosterone back pain
mohs surgery: patient satisfaction & quality of life (qol)

Conditions: Quality of Life

Summary: the purpose of this study is to examine whether there is significant difference between two groups: extra care (ec) and usual care (uc) in improvement of patients' quality-of-life (qol) scores between the baseline and 90-day post-surgery in patients undergoing mohs micrographic surgery (mms).


Eligibility criteria:
inclusion criteria: 1. female and/or male subjects undergoing mohs micrographic surgery for basal cell carcinoma (bcc) and/or squamous cell carcinoma (scc). 2. subjects must be at least 18 years of age. exclusion criteria: 1. subjects who are not able to complete the surveys (pre-surgery, 1 week post-surgery, and 3 months post- surgery) 2. subjects under the age 18 3. subjects unable to consent 4. subjects who are not undergoing mohs micrographic surgery for basal cell carcinoma (bcc) or squamous cell carcinoma (scc).
exparel administered into the tap for analgesia in subjects undergoing open total abdominal hysterectomy

Conditions: Postoperative Pain

Summary: the primary objective of this study is to determine the optimal of two different volumes of exparel 266 mg when administered via infiltration into the transversus abdominis plane (tap) for prolonged postoperative analgesia in subjects undergoing open total abdominal hysterectomy.

this is a prospective, open-label, non-randomized study with two treatment groups differing only in the volume of exparel infiltrated into the tap. all subjects will undergo an open total abdominal hysterectomy. the dose of exparel for the taps will be the same for all 20 subjects, 133 mg on the right side of the abdomen and 133 mg on the left side of the abdomen.

Eligibility criteria:
inclusion criteria: * females, 18-75 years of age inclusive. * american society of anesthesiologist (asa) physical status 1-3. * undergoing open total abdominal hysterectomy (i.e., laparoscopic procedures are not sufficient) without any concurrent surgical procedure(s). * physically and mentally able to participate in the study and complete all study assessments. * able to give fully informed consent to participate in this study after demonstrating a good understanding of the risks and benefits of the tap. exclusion criteria: * demonstrated hypersensitivity or idiosyncratic reactions to amide-type local anesthetics. * any subject whose anatomy, or surgical procedure, in the opinion of the investigator, might preclude the potential successful performance of a tap. * any subject who in the opinion of the investigator might be harmed or be a poor candidate for participation in the study. * any subject, who in the opinion of the investigator, is on chronic pain medicine. * subjects who have received any investigational drug within 30 days prior to study drug administration, or planned administration of another investigational product or procedure during their participation in this study.

Keywords: hysterectomy analgesia
dronaderone to prevent recurrent implantable cardioverter defibrillator (icd) shocks

Conditions: ICD; ICD SHOCKS; DRONEDARONE

Summary: recurrent icd shocks are a serious problem in pts with icd. treatment failure with other antiarrhythmics and ablation are common. dronedarone is a new antiarrhythmic drug with ion channel properties similar to amiodarone. several case reports have shown promising results with dronedarone for this patient population.


Eligibility criteria:
inclusion criteria: * recurernt icd shocks depite other antiarrhythmic drug therapy exclusion criteria: * chf nyha iv or decmpensated iii * permanent af * liver dysfuncion * cr clearance \<30
v-y flap for anal stenosis

Conditions: Anal Stenosis

Summary: anal stenosis is a common complication after massive open hemorrhoidectomy. it interferes with the patient daily activities. many interventions were described, but there is no standard treatment. data were always lost about the best intervention. in this study we try to discover if v-y advancement flap can effectively treat anal stenosis or not.


Eligibility criteria:
inclusion criteria: * patients of both sexes aged ≥ 18years old with moderate to severe post- hemorrhoidectomy anal stenosis exclusion criteria: * pregant females * patient with prior irridiation * patient with t.b * patient with crohn's disease

Keywords: anal stenosis, anoplasty, v-y advancement flap
using test of scm for detection breast cancer

Conditions: Malignant Breast Cancer, Benign Breast Lesions

Summary: in our previous research, we have shown that women that have breast cancer have a population of lymphocytes that recognizes specific antigen and there cytoplasmic matrix goes through physical change a short time after exposure in vitro to the same antigen. this change can be measured by polarization changes of fluorescent light emitted by fda (fluorescein diacetate) labeled cells. further test that we performed showed that those differences are also shown in a benign situation that known as indicator for a high risk for developing breast cancer within 10-15 years. the incidence of the expression of these lymphocytes correlates with the histopathological picture as it is related in high risk for the developing the disease. in this work we will expand the scope of the procedure to early detection of the cancerous process in breast lesions by fitzgibbon's risk categories for the development invasive carcinoma of the breast. in the proposed work we intend to use specific antigen muc1 for breast cancer. this study is a continuation of our published work in the "the breast "


Eligibility criteria:
inclusion criteria: women carrying benign breast lesions will be further divided and analyzed according to the fitzgibbon's risk categories for invasive cancer risk (4). the fitzgibbon's categories are: 1. no increased risk group including adenosis (other than sclerotic), duct ectasia fibroadenoma without complex features, 2. slightly increased risk group (1.5-20 times) which includes fibroadenoma with complex features, moderate or florid hyperplasia without atypia, sclerosing adenosis, 3. moderately increased risk group (4.0-5.0 times) includes atypical ductal and lobular hyperplasia and 4. markedly increased risk group (8.0-10.0 times) which includes ductal and lobular carcinomas in situ following the blood collection, detailed relevant clinical information of the patient will be registered in a case record form. the data will include: age, country of birth, last menstrual period, lactation, number of children, age at first full-term pregnancy, age at onset of menopause, family history, medication, mammography findings, fna results, tumor size, histological findings, biopsies, disease staging, and other relevant clinical information. exclusion criteria: 1. pregnancy, 2. experiencing menstruation, or 3. under hormonal or drug treatment.

Keywords: breast cancer, facs, scm, malignant, benign, lymphocytes
prevalence of lactose intolerance following stem cell transplantation

Conditions: Lactose Intolerance

Summary: it is currently assumed that all patients are lactose intolerant post bone marrow transplantation. this pilot study is to assess what the incidence of lactose intolerance is after bone marrow transplantation in children. this will be done using a lactose breath test.

all pediatric patients over the age of 4 years who are scheduled for a stem cell transplant will be approached to assess whether what the incidence of lactose intolerance is in the post transplant period and how quickly recovery occurs. a baseline lactose and lactulose breath test will be performed followed by repeat lactose breath tests starting 2 weeks after day 0 and repeated every fortnight for 10 weeks. stool ph and reducing substances will be checked at the time of the breath tests to see if there is any correlation.

Eligibility criteria:
inclusion criteria: * all patients planned to undergo a stem cell transplant. exclusion criteria: * refusal to participate * unable to perform breath tests on request (generally under the age of 4 years.)

Keywords: pilot, pediatric, stem cell transplant, lactose intolerance